<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92360">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841554</url>
  </required_header>
  <id_info>
    <org_study_id>CB1-2</org_study_id>
    <nct_id>NCT01841554</nct_id>
  </id_info>
  <brief_title>Cardioband With Transfemoral Delivery System</brief_title>
  <official_title>Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valtech Cardio Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valtech Cardio Ltd</source>
  <oversight_info>
    <authority>France:ANSM</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance and safety of the Cardioband Adjustable Annuloplasty System for
      repair of functional mitral regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety • Overall rate of Major Serious Adverse Events (SAEs) and serious adverse safety</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall rate of Major Serious Adverse Events (SAEs)* and serious adverse device effects (SADE) until hospital discharge and at post-operative 30 days.
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>MR Severity at 6 and 12 months
Change in 6 MWT  in 6 and 12 months
Change in quality of life (MLHFQ) at 6 and 12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Performance</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Technical success rate of the implantation of the Cardioband
Technical feasibility of Cardioband adjustment
Cardioband ability to reduce mitral valve regurgitation (MR) Intra-procedure, at hospital discharge, and at 30 days.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardioband</intervention_name>
    <arm_group_label>Single</arm_group_label>
    <other_name>With Transfemoral delivery system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Moderate to severe functional MR

          -  Symptomatic Patients (NYHA ClassII-IV) despite optimal medical therapy , including
             CRT if indicated.

          -  LVEF ≥ 25%, LVEDD ≤ 65mm

          -  Subject is high risk to undergo MV surgery (as assessed by a surgeon and a
             cardiologist, at the site)

          -  Transseptal catheterization and femoral vein access is determined to be  feasible

          -  Subject is able and willing to give informed consent and follow protocol procedures

        Exclusion Criteria:

          -  Active bacterial endocarditis

          -  Severe organic lesions with retracted chordae or congenital malformations with lack
             of valvular tissue

          -  Heavily calcified annulus or leaflets

          -  Subjects in whom transesophageal echocardiography is contraindicated

          -  Untreated clinically significant CAD requiring revascularization

          -  CRT implant within 3 months prior to procedure

          -  Any percutaneous coronary, carotid, endovascular intervention or carotid surgery
             within 30 days or any coronary or endovascular surgery within 3 months

          -  CVA or TIA within 6 months or severe carotid stenosis (&gt;70% by Ultra sound)

          -  Renal insufficiency requiring dialysis

          -  Life expectancy of less than twelve months

          -  Subject is participating in concomitant research studies of investigational products
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bichat hospital</name>
      <address>
        <city>Paris</city>
        <zip>18 75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alec Vahanian, MD</last_name>
      <phone>+33140256735/60</phone>
    </contact>
    <investigator>
      <last_name>Alec Vahanian, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik, St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>5 20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl-Heinz Kuck, Prof</last_name>
    </contact>
    <contact_backup>
      <phone>+49401818852305</phone>
    </contact_backup>
    <investigator>
      <last_name>Karl-Heinz Kuck, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve</keyword>
  <keyword>Annuloplasty</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
